Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, 535 E70th Street, New York, NY, 10021, USA.
Center of Research of Immunopathology and Rare Diseases, University of Turin, Turin, Italy.
Curr Rheumatol Rep. 2021 May 1;23(6):45. doi: 10.1007/s11926-021-01008-8.
APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)-positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions.
APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients.
抗磷脂综合征（APS）行动是一个国际研究网络，旨在设计和开展大规模、多中心的持续性抗磷脂抗体（aPL）阳性患者研究。鉴于该网络自成立以来在过去十年中研究活动不断扩大，本文旨在回顾 APS 行动的科学贡献以及未来方向。
APS 行动通过内部和外部研究人员在结局、干预和机制性抗磷脂综合征（APS）研究方面的合作，取得了更多的国际合作。这与核心实验室工作的重大进展相关联，核心实验室工作表明，实验室可以通过使用相同的试剂、分析仪类型和方案来实现良好的 aPL 检测一致性。APS 行动将继续发现现有 aPL/APS 文献中的空白，设计机制研究以阐明潜在机制，并开展前瞻性、大规模的临床研究，所有这些都是为了实现早期诊断和改善 aPL 阳性患者管理的最终目标。
